What is the 13F Pro Quality Score for PBH?

13F Pro ranks Prestige Consumer Healthcare Inc. (PBH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PBH's current score at https://13fpro.ai/company/PBH (free sign-up required for the full ranking).

Which hedge funds own the most PBH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PBH include BlackRock,, ARIEL INVESTMENTS,, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PBH as soon as new 13F filings post.

Where does 13F Pro source PBH data?

All Prestige Consumer Healthcare Inc. fundamentals and ownership data come directly from SEC EDGAR. Prestige Consumer Healthcare Inc. files with the SEC under CIK 1295947. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PBH in?

Prestige Consumer Healthcare Inc. (PBH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are PBH's largest expenses?

Prestige Consumer Healthcare Inc.'s latest 10-Q reports these as the largest expense items: Cost of sales (excluding depreciation) ($126.5M, +18.5% YoY); Advertising and marketing ($34.7M, -0.8% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2027 (quarter ended June 30, 2026).

How often is PBH research updated on 13F Pro?

PBH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Prestige Consumer Healthcare Inc.(PBH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1295947 PBH stock profile & AI dashboard →

13F Pro Quality Score

53.7/100

Rank #1,372 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

23.3/100

Profitability

68.2/100

Balance Sheet

66.6/100

Earnings Quality

73.2/100

Free Cash Flow

74.5/100

Institutional Flow

35.0/100

Revenue Scale

51.7/100

Dilution Risk

57.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PBH Scores 54/100

exact factor attribution · 2026-09-11

PBH's composite is driven by free cash flow and profitability, held back by revenue growth and earnings growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Free cash flow

+3.7 pts

75th pct

Profitability

+2.7 pts

68th pct

Earnings quality

+2.3 pts

73th pct

Capital efficiency

+1.7 pts

67th pct

Shareholder dilution

+0.4 pts

57th pct

Scale

+0.3 pts

52th pct

Institutional flow

-0.8 pts

35th pct

Earnings growth

-1.2 pts

26th pct

Revenue growth

-5.3 pts

23th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PBH Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Prestige Consumer Healthcare Inc. (PBH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PBH at 53.7/100 on a 32-signal composite quality model, placing it at rank #1,372 of 2,961 stocks — the top half of the AI-ranked universe. Areas of concern include revenue growth (23.3) and institutional flow (35.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Prestige Consumer Healthcare Inc. reports quarterly revenue of $265.7M, net income of $29.2M, free cash flow of $67.1M. Top institutional holders of PBH by reported 13-F value include BlackRock, ARIEL INVESTMENTS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PBH trades on the NYSE exchange and files with the SEC under CIK 1295947. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Prestige Consumer Healthcare Inc. directly from SEC EDGAR. Prestige Consumer Healthcare Inc.'s 13F Pro composite quality score has ranged between 53 and 67 since 2021, currently 53.7 — a declining long-term trajectory across 67 quarterly and live scoring snapshots.

What's Driving PBH's Business? Latest 10-Q Breakdown

AI-extracted from Prestige Consumer Healthcare Inc.'s 10-Q filed 2026-08-06 — Q1 FY2027 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

PBH acquired Breathe Right and related brands for $1.045B on June 12, 2026, raising total revenue 6.5% YoY to $265.7M, though gross margin compressed 290 bps to 51.3% due to acquisition-related costs and inventory step-up amortization.

Biggest Revenue Drivers

North American OTC Healthcare$226.2M+6.4% YoY

Increases in Wellness/Sleep/Other (+165.7%), Gastrointestinal (+7.9%), Dermatologicals (+9.9%), and Cough/Cold/Allergy (+17.0%), partly offset by decreases in Women's Health (-5.1%) and Pain Relief (-3.8%).

International OTC Healthcare$39.5M+6.9% YoY

Increases in Wellness/Sleep/Other and Gastrointestinal, partly offset by decrease in Pain Relief.

Biggest Revenue Drivers

Total revenue: $265.7M+6.5% YoY

North American OTC Healthcare$226.2M+6.4% YoY

International OTC Healthcare$39.5M+6.9% YoY

Increases in Wellness/Sleep/Other and Gastrointestinal, partly offset by decrease in Pain Relief.

Largest Expense Items

Cost of sales (excluding depreciation)$126.5M+18.5% YoY

Increase driven by amortization of acquired inventory fair value step-up and costs related to improving and optimizing acquired Pillar5 facility.

Advertising and marketing$34.7M-0.8% YoY

Relatively flat versus prior year.

Margins: Gross margin contracted 290 basis points to 51.3% in Q1 FY2027 from 56.2% in Q1 FY2026, primarily driven by amortization of inventory fair value step-up from the OTC Wellness Business acquisition and costs associated with improving the acquired Pillar5 facility. Contribution margin (gross profit less advertising/marketing) declined 400 bps to 38.2%.

Watch Items from the Filing

Walmart represents 19% of Q1 FY2027 revenues (down from 22% YoY); Amazon 16% (up from 12% YoY). Two customers account for 35% of gross revenues, creating material customer concentration risk.
One privately owned pharmaceutical manufacturer supplies approximately 22% of gross revenues and accounted for a significant portion of that supplier's revenues; no long-term contract with certain other manufacturers creates supply disruption risk.
Sterile ophthalmic manufacturing capacity constraints persist: all sterile eye care manufacturing sites have undergone health authority inspections, with remediation activities potentially causing ongoing supply variability, reduced capacity, and production delays.
Total debt increased to $2.045B from $1.0B at March 31, 2026 due to $1.045B Term Loan for OTC Wellness Business acquisition and $95M drawn for LaCorium Health (July 1, 2026); subsequent $400M Senior Notes issuance redeemed $400M 2019 notes.
Pro forma Q1 FY2027 revenues would have been $297.5M (vs. actual $265.7M) and pro forma net income $36.4M (vs. actual $29.2M) had OTC Wellness Business been included from April 1, 2025; excludes anticipated synergies.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$265.7M

Net Income

Q2 2026

$29.2M

Free Cash Flow

Q2 2026

$67.1M

ROIC

Q2 2026

5.3%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-4.3% YoY

$1.09BFY 2026

FY23 $1.13BFY24 $1.13BFY25 $1.14BFY26 $1.09B

Net Income

-11.3% YoY

$190.3MFY 2026

FY23 $-82.3MFY24 $209.3MFY25 $214.6MFY26 $190.3M

Operating Income

-8.1% YoY

$309.4MFY 2026

FY23 $-22.4MFY24 $342.4MFY25 $336.8MFY26 $309.4M

EPS (Diluted)

-8.9% YoY

$3.91FY 2026

FY23 $-1.65FY24 $4.17FY25 $4.29FY26 $3.91

Total Assets

+2.7% YoY

$3.49BFY 2026

FY23 $3.35BFY24 $3.32BFY25 $3.40BFY26 $3.49B

Total Debt

+0.2% YoY

$994.0MFY 2026

FY23 $1.36BFY24 $1.14BFY25 $992.4MFY26 $994.0M

Op. Cash Flow

+2.4% YoY

$257.6MFY 2026

FY23 $229.7MFY24 $248.9MFY25 $251.5MFY26 $257.6M

Free Cash Flow

+1.3% YoY

$246.4MFY 2026

FY23 $221.9MFY24 $239.4MFY25 $243.3MFY26 $246.4M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$1.09B -4.3%	$1.14B +1.1%	$1.13B -0.2%	$1.13B +3.8%	$1.09B +15.2%	$943.4M
Net Income	$190.3M -11.3%	$214.6M +2.5%	$209.3M +354.3%	$-82.3M -140.1%	$205.4M +24.7%	$164.7M
Operating Income	$309.4M -8.1%	$336.8M -1.7%	$342.4M +1627.7%	$-22.4M -106.8%	$329.9M +10.9%	$297.4M
EPS (Diluted)	$3.91 -8.9%	$4.29 +2.9%	$4.17 +352.7%	$-1.65 -140.8%	$4.04 +24.3%	$3.25
Total Assets	$3.49B +2.7%	$3.40B +2.5%	$3.32B -1.1%	$3.35B -8.6%	$3.67B +7.0%	$3.43B
Total Debt	$994.0M +0.2%	$992.4M -12.6%	$1.14B -16.5%	$1.36B -7.9%	$1.48B -0.2%	$1.48B
Operating Cash Flow	$257.6M +2.4%	$251.5M +1.0%	$248.9M +8.4%	$229.7M -11.6%	$259.9M +10.3%	$235.6M
Free Cash Flow	$246.4M +1.3%	$243.3M +1.6%	$239.4M +7.9%	$221.9M -11.3%	$250.3M +17.3%	$213.4M

Get alerted when PBH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Prestige Consumer Healthcare Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PBH

BlackRock, Inc.
$370.2M7,831,333 sh
ARIEL INVESTMENTS, LLC
$230.1M4,868,711 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$133.6M2,825,340 sh
DIMENSIONAL FUND ADVISORS LP
$125.8M2,661,291 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$110.2M2,331,821 sh
VANGUARD CAPITAL MANAGEMENT LLC
$101.0M2,136,944 sh
STATE STREET CORP
$100.0M2,116,513 sh
BRANDES INVESTMENT PARTNERS, LP
$97.0M2,051,060 sh
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
$88.5M1,872,023 sh
GEODE CAPITAL MANAGEMENT, LLC
$74.3M1,571,742 sh

Fund	Value	Shares
BlackRock, Inc.	$370.2M	7,831,333
ARIEL INVESTMENTS, LLC	$230.1M	4,868,711
VANGUARD PORTFOLIO MANAGEMENT LLC	$133.6M	2,825,340
DIMENSIONAL FUND ADVISORS LP	$125.8M	2,661,291
FULLER & THALER ASSET MANAGEMENT, INC.	$110.2M	2,331,821
VANGUARD CAPITAL MANAGEMENT LLC	$101.0M	2,136,944
STATE STREET CORP	$100.0M	2,116,513
BRANDES INVESTMENT PARTNERS, LP	$97.0M	2,051,060
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC	$88.5M	1,872,023
GEODE CAPITAL MANAGEMENT, LLC	$74.3M	1,571,742

Companies Similar to PBH

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

Pediatrix Medical Group, Inc.

AI score

Similar quality profile · 17 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.SILVERCREST ASSET MANAGEMENT GROUP LLC BRANDES INVESTMENT PARTNERS, LP

HAE

HAEMONETICS CORP

AI score

Similar quality profile · 17 shared holders

ARIEL INVESTMENTS, LLC Boston Trust Walden Corp SILVERCREST ASSET MANAGEMENT GROUP LLC

ITGR

Integer Holdings Corp

AI score

Similar quality profile · 16 shared holders

SILVERCREST ASSET MANAGEMENT GROUP LLC FULLER & THALER ASSET MANAGEMENT, INC.ARMISTICE CAPITAL, LLC

NGVT

Ingevity Corp

AI score

Similar quality profile · 14 shared holders

RICE HALL JAMES & ASSOCIATES, LLC Leeward Investments, LLC - MA WEDGE CAPITAL MANAGEMENT L L P/NC

NVST

Envista Holdings Corp

AI score

Similar quality profile · 18 shared holders

ARIEL INVESTMENTS, LLC FULLER & THALER ASSET MANAGEMENT, INC.Leeward Investments, LLC - MA

CNMD

CONMED Corp

AI score

Similar quality profile · 15 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.SILVERCREST ASSET MANAGEMENT GROUP LLC HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC

PCRX

Pacira BioSciences, Inc.

AI score

Similar quality profile · 15 shared holders

MARTINGALE ASSET MANAGEMENT L P WEDGE CAPITAL MANAGEMENT L L P/NC RICE HALL JAMES & ASSOCIATES, LLC

MMSI

MERIT MEDICAL SYSTEMS INC

AI score

Similar quality profile · 22 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.WESTWOOD HOLDINGS GROUP INC Boston Trust Walden Corp

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PBH on your watchlist

Track score changes the day Prestige Consumer Healthcare Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PBH a good stock to buy?

13F Pro's AI-powered analysis of Prestige Consumer Healthcare Inc. (PBH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PBH are available on the PBH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PBH is classified as a mid company.

Which hedge funds own PBH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PBH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Prestige Consumer Healthcare Inc.'s investment landscape.